Trials / Suspended
SuspendedNCT04121143
A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults
Multicenter, Placebo-controlled, Parallel-randomized, Double-blind, Phase II Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of SHR-1314 Injection With Moderate to Severe Plaque Psoriasis in Adults
- Status
- Suspended
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, placebo-controlled, parallel-randomized, double-blind, phase II study to investigate the efficacy, safety, tolerability and Pharmacokinetics of SHR-1314 injection with moderate to severe plaque psoriasis in adults
Detailed description
This study was a multicenter, parallel, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy ,safety, tolerance, and pharmacokinetics (PK) of different SHR-1314 dosing regimens in moderate to severe chronic plaque psoriasis in adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IL-17A Antagonist | SHR-1314 subcutaneous injection |
| BIOLOGICAL | Placebos | placebo subcutaneous injection to maintain consistency and to prevent blindness |
Timeline
- Start date
- 2019-11-09
- Primary completion
- 2020-06-30
- Completion
- 2020-12-30
- First posted
- 2019-10-09
- Last updated
- 2020-03-23
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04121143. Inclusion in this directory is not an endorsement.